Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 May;118(2):414–420. doi: 10.1111/j.1476-5381.1996.tb15418.x

Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo.

D C Brown 1, L J Steward 1, J Ge 1, N M Barnes 1
PMCID: PMC1909619  PMID: 8735646

Abstract

1. The ability of angiotensin II to modulate dopamine release from rat striatal slices in vitro and in the intact rat striatum in vivo was assessed by the microdialysis technique. 2. In slices of rat striatum, angiotensin II (0.1-1.0 microM) induced a concentration-related increase in endogenous dopamine release which was maximal (approximately 250% above basal levels) within the first 2-4 min of agonist application and subsequently declined to near basal values. The angiotensin II-induced increase in dopamine release was Ca(2+)-dependent and was completely antagonized by the selective AT1 receptor antagonist, losartan (1.0 microM). In contrast, the AT2 receptor antagonist, PD123177 (1.0 microM) failed to modify the angiotensin II-induced response. Neither antagonist alone modified basal dopamine release from striatal slices. 3. In freely moving rats, angiotensin II (1.0-10 microM; administered via the microdialysis probe) induced a concentration-related increase in extracellular levels of dopamine which was maximal (approximately 150% above basal levels) within 20-40 min of agonist application and subsequently declined. The angiotensin II (10 microM)-induced increase in extracellular levels of dopamine was completely antagonized by the AT1 receptor antagonist, losartan (0.1-1.0 microM; administered via the microdialysis probe) but not by the AT2 receptor antagonist, PD123177 (1.0 microM; administered via the microdialysis probe). Neither antagonist alone modified basal extracellular levels of dopamine. 4. Homogenate radioligand binding studies with [125I]-angiotensin II (0.1 nm) identified relatively low levels of specific binding sites in rat striatal homogenates compared to homogenates of pyriform cortex (51.3 +/- 9.2 and 651.3 +/- 55.1 fmol g-1 wet weight, respectively, mean +/- s.e.mean, n = 3; non-specific binding defined by unlabelled angiotensin II). The majority of the specific [125I]-angiotensin II (0.1 nM) binding in the striatal and pyriform cortex homogenates was sensitive to the selective AT1 receptor antagonist, losartan (1.0 microM). 5. In conclusions the present study provides direct evidence that angiotensin II acting via the AT1 receptor subtype facilitates the release of dopamine in the rat striatum in vitro and in vivo. This receptor-mediated response may account for the modulation of dopamine-mediated behavioural responses by antagonists of the AT1 receptor and inhibitors of angiotensin converting enzyme.

Full text

PDF
414

Images in this article

417Figure 3
on p.417

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abdellatif M. M., Neubauer C. F., Lederer W. J., Rogers T. B. Angiotensin-induced desensitization of the phosphoinositide pathway in cardiac cells occurs at the level of the receptor. Circ Res. 1991 Sep;69(3):800–809. doi: 10.1161/01.res.69.3.800. [DOI] [PubMed] [Google Scholar]
  2. Allen A. M., MacGregor D. P., Chai S. Y., Donnan G. A., Kaczmarczyk S., Richardson K., Kalnins R., Ireton J., Mendelsohn F. A. Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia. Ann Neurol. 1992 Sep;32(3):339–344. doi: 10.1002/ana.410320306. [DOI] [PubMed] [Google Scholar]
  3. Balmforth A. J., Bryson S. E., Aylett A. J., Warburton P., Ball S. G., Pun K. T., Middlemiss D., Drew G. M. Comparative pharmacology of recombinant rat AT1A, AT1B and human AT1 receptors expressed by transfected COS-M6 cells. Br J Pharmacol. 1994 May;112(1):277–281. doi: 10.1111/j.1476-5381.1994.tb13064.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barnes J. M., Barnes N. M., Costall B., Coughlan J., Kelly M. E., Naylor R. J., Tomkins D. M., Williams T. J. Angiotensin-converting enzyme inhibition, angiotensin, and cognition. J Cardiovasc Pharmacol. 1992;19 (Suppl 6):S63–S71. doi: 10.1097/00005344-199219006-00011. [DOI] [PubMed] [Google Scholar]
  5. Barnes J. M., Steward L. J., Barber P. C., Barnes N. M. Identification and characterisation of angiotensin II receptor subtypes in human brain. Eur J Pharmacol. 1993 Jan 19;230(3):251–258. doi: 10.1016/0014-2999(93)90558-y. [DOI] [PubMed] [Google Scholar]
  6. Barnes N. M., Cheng C. H., Costall B., Ge J., Naylor R. J. Differential modulation of extracellular levels of 5-hydroxytryptamine in the rat frontal cortex by (R)- and (S)-zacopride. Br J Pharmacol. 1992 Sep;107(1):233–239. doi: 10.1111/j.1476-5381.1992.tb14492.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Barnes N. M., Costall B., Kelly M. E., Murphy D. A., Naylor R. J. Anxiolytic-like action of DuP753, a non-peptide angiotensin II receptor antagonist. Neuroreport. 1990 Sep;1(1):20–21. doi: 10.1097/00001756-199009000-00006. [DOI] [PubMed] [Google Scholar]
  8. Barnes N. M., Costall B., Kelly M. E., Murphy D. A., Naylor R. J. Cognitive enhancing actions of PD123177 detected in a mouse habituation paradigm. Neuroreport. 1991 Jun;2(6):351–353. doi: 10.1097/00001756-199106000-00013. [DOI] [PubMed] [Google Scholar]
  9. Bottari S. P., de Gasparo M., Steckelings U. M., Levens N. R. Angiotensin II receptor subtypes: characterization, signalling mechanisms, and possible physiological implications. Front Neuroendocrinol. 1993 Apr;14(2):123–171. doi: 10.1006/frne.1993.1005. [DOI] [PubMed] [Google Scholar]
  10. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1006/abio.1976.9999. [DOI] [PubMed] [Google Scholar]
  11. Brasch H., Sieroslawski L., Dominiak P. Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype 1 receptors. Hypertension. 1993 Nov;22(5):699–704. doi: 10.1161/01.hyp.22.5.699. [DOI] [PubMed] [Google Scholar]
  12. Brown L., Sernia C. Angiotensin receptors in cardiovascular diseases. Clin Exp Pharmacol Physiol. 1994 Oct;21(10):811–818. doi: 10.1111/j.1440-1681.1994.tb02450.x. [DOI] [PubMed] [Google Scholar]
  13. Bunnemann B., Iwai N., Metzger R., Fuxe K., Inagami T., Ganten D. The distribution of angiotensin II AT1 receptor subtype mRNA in the rat brain. Neurosci Lett. 1992 Aug 17;142(2):155–158. doi: 10.1016/0304-3940(92)90362-b. [DOI] [PubMed] [Google Scholar]
  14. Del Monte M., Subissi A. Muscarinic receptor subtypes involved in neural bronchoconstriction in the guinea-pig. Pharmacol Res. 1992 Feb-Mar;25 (Suppl 1):9–10. doi: 10.1016/1043-6618(92)90515-d. [DOI] [PubMed] [Google Scholar]
  15. Dennes R. P., Barnes J. C. Attenuation of scopolamine-induced spatial memory deficits in the rat by cholinomimetic and non-cholinomimetic drugs using a novel task in the 12-arm radial maze. Psychopharmacology (Berl) 1993;111(4):435–441. doi: 10.1007/BF02253533. [DOI] [PubMed] [Google Scholar]
  16. Dwoskin L. P., Jewell A. L., Cassis L. A. DuP 753, a nonpeptide angiotensin II-1 receptor antagonist, alters dopaminergic function in rat striatum. Naunyn Schmiedebergs Arch Pharmacol. 1992 Feb;345(2):153–159. doi: 10.1007/BF00165730. [DOI] [PubMed] [Google Scholar]
  17. Dzau V. J., Mukoyama M., Pratt R. E. Molecular biology of angiotensin receptors: target for drug research? J Hypertens Suppl. 1994 Jul;12(2):S1–S5. [PubMed] [Google Scholar]
  18. Finocchiaro L. M., Goldstein D. J., Finkielman S., Nahmod V. E. Interaction of angiotensin II with the cholinergic and noradrenergic systems in the rat pineal gland: regulation of indole metabolism. J Endocrinol. 1990 Jul;126(1):59–66. doi: 10.1677/joe.0.1260059. [DOI] [PubMed] [Google Scholar]
  19. Gehlert D. R., Gackenheimer S. L., Schober D. A. Autoradiographic localization of subtypes of angiotensin II antagonist binding in the rat brain. Neuroscience. 1991;44(2):501–514. doi: 10.1016/0306-4522(91)90073-w. [DOI] [PubMed] [Google Scholar]
  20. Georgiev V. Involvement of transmitter mechanisms in the behavioural effects of angiotensin II. Pol J Pharmacol Pharm. 1990 Nov-Dec;42(6):553–562. [PubMed] [Google Scholar]
  21. Georgiev V., Kambourova T. Behavioural effects of angiotensin II in the mouse following MPTP administration. Gen Pharmacol. 1991;22(4):625–630. doi: 10.1016/0306-3623(91)90067-g. [DOI] [PubMed] [Google Scholar]
  22. Huang Y., Rogers J., Henderson G. Effects of angiotensin II on [3H]noradrenaline release and phosphatidylinositol hydrolysis in the parietal cortex and locus coeruleus of the rat. J Neurochem. 1987 Nov;49(5):1541–1549. doi: 10.1111/j.1471-4159.1987.tb01025.x. [DOI] [PubMed] [Google Scholar]
  23. Inagami T., Guo D. F., Kitami Y. Molecular biology of angiotensin II receptors: an overview. J Hypertens Suppl. 1994 Dec;12(10):S83–S94. [PubMed] [Google Scholar]
  24. Iwai N., Yamano Y., Chaki S., Konishi F., Bardhan S., Tibbetts C., Sasaki K., Hasegawa M., Matsuda Y., Inagami T. Rat angiotensin II receptor: cDNA sequence and regulation of the gene expression. Biochem Biophys Res Commun. 1991 May 31;177(1):299–304. doi: 10.1016/0006-291x(91)91982-i. [DOI] [PubMed] [Google Scholar]
  25. Kaiser F. C., Palmer G. C., Wallace A. V., Carr R. D., Fraser-Rae L., Hallam C. Antianxiety properties of the angiotensin II antagonist, DUP 753, in the rat using the elevated plus-maze. Neuroreport. 1992 Oct;3(10):922–924. doi: 10.1097/00001756-199210000-00026. [DOI] [PubMed] [Google Scholar]
  26. Kakar S. S., Riel K. K., Neill J. D. Differential expression of angiotensin II receptor subtype mRNAs (AT-1A and AT-1B) in the brain. Biochem Biophys Res Commun. 1992 Jun 15;185(2):688–692. doi: 10.1016/0006-291x(92)91680-o. [DOI] [PubMed] [Google Scholar]
  27. Kakar S. S., Sellers J. C., Devor D. C., Musgrove L. C., Neill J. D. Angiotensin II type-1 receptor subtype cDNAs: differential tissue expression and hormonal regulation. Biochem Biophys Res Commun. 1992 Mar 31;183(3):1090–1096. doi: 10.1016/s0006-291x(05)80302-x. [DOI] [PubMed] [Google Scholar]
  28. Kuttan S. C., Sim M. K. Angiotensin II-induced tachyphylaxis in aortas of normo- and hypertensive rats: changes in receptor affinity. Eur J Pharmacol. 1993 Mar 2;232(2-3):173–180. doi: 10.1016/0014-2999(93)90771-9. [DOI] [PubMed] [Google Scholar]
  29. Lippoldt A., Paul M., Fuxe K., Ganten D. The brain renin-angiotensin system: molecular mechanisms of cell to cell interactions. Clin Exp Hypertens. 1995 Jan-Feb;17(1-2):251–266. doi: 10.3109/10641969509087069. [DOI] [PubMed] [Google Scholar]
  30. MacGregor D. P., Murone C., Song K., Allen A. M., Paxinos G., Mendelsohn F. A. Angiotensin II receptor subtypes in the human central nervous system. Brain Res. 1995 Mar 27;675(1-2):231–240. doi: 10.1016/0006-8993(95)00076-3. [DOI] [PubMed] [Google Scholar]
  31. Mendelsohn F. A., Jenkins T. A., Berkovic S. F. Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats. Brain Res. 1993 Jun 11;613(2):221–229. doi: 10.1016/0006-8993(93)90902-y. [DOI] [PubMed] [Google Scholar]
  32. Mendelsohn F. A., Quirion R., Saavedra J. M., Aguilera G., Catt K. J. Autoradiographic localization of angiotensin II receptors in rat brain. Proc Natl Acad Sci U S A. 1984 Mar;81(5):1575–1579. doi: 10.1073/pnas.81.5.1575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Millan M. A., Jacobowitz D. M., Aguilera G., Catt K. J. Differential distribution of AT1 and AT2 angiotensin II receptor subtypes in the rat brain during development. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11440–11444. doi: 10.1073/pnas.88.24.11440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Morgan J. M., Routtenberg A. Angiotensin injected into the neostriatum after learning disrupts retention performance. Science. 1977 Apr 1;196(4285):87–89. doi: 10.1126/science.402696. [DOI] [PubMed] [Google Scholar]
  35. Murphy T. J., Alexander R. W., Griendling K. K., Runge M. S., Bernstein K. E. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature. 1991 May 16;351(6323):233–236. doi: 10.1038/351233a0. [DOI] [PubMed] [Google Scholar]
  36. Qadri F., Badoer E., Stadler T., Unger T. Angiotensin II-induced noradrenaline release from anterior hypothalamus in conscious rats: a brain microdialysis study. Brain Res. 1991 Nov 1;563(1-2):137–141. doi: 10.1016/0006-8993(91)91526-7. [DOI] [PubMed] [Google Scholar]
  37. Reagan L. P., Ye X., Maretzski C. H., Fluharty S. J. Down-regulation of angiotensin II receptor subtypes and desensitization of cyclic GMP production in neuroblastoma N1E-115 cells. J Neurochem. 1993 Jan;60(1):24–31. doi: 10.1111/j.1471-4159.1993.tb05818.x. [DOI] [PubMed] [Google Scholar]
  38. Reid I. A. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol. 1992 Jun;262(6 Pt 1):E763–E778. doi: 10.1152/ajpendo.1992.262.6.E763. [DOI] [PubMed] [Google Scholar]
  39. Simonnet G., Giorguieff-Chesselet M. F. Stimulating effect of angiotensin II on the spontaneous release of newly synthetized [3H]dopamine in rat striatal slices. Neurosci Lett. 1979 Dec;15(2-3):153–158. doi: 10.1016/0304-3940(79)96105-6. [DOI] [PubMed] [Google Scholar]
  40. Sirett N. E., McLean A. S., Bray J. J., Hubbard J. I. Distribution of angiotensin II receptors in rat brain. Brain Res. 1977 Feb 18;122(2):299–312. doi: 10.1016/0006-8993(77)90296-7. [DOI] [PubMed] [Google Scholar]
  41. Stadler T., Veltmar A., Qadri F., Unger T. Angiotensin II evokes noradrenaline release from the paraventricular nucleus in conscious rats. Brain Res. 1992 Jan 8;569(1):117–122. doi: 10.1016/0006-8993(92)90377-l. [DOI] [PubMed] [Google Scholar]
  42. Steckelings U. M., Bottari S. P., Unger T. Angiotensin receptor subtypes in the brain. Trends Pharmacol Sci. 1992 Sep;13(9):365–368. doi: 10.1016/0165-6147(92)90110-r. [DOI] [PubMed] [Google Scholar]
  43. Steward L. J., Ge J., Stowe R. L., Brown D. C., Bruton R. K., Stokes P. R., Barnes N. M. Ability of 5-HT4 receptor ligands to modulate rat striatal dopamine release in vitro and in vivo. Br J Pharmacol. 1996 Jan;117(1):55–62. doi: 10.1111/j.1476-5381.1996.tb15154.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Tsuda A., Tanaka M., Georgiev V., Emoto H. Effects of angiotensin II on behavioral responses of defensive burying paradigm in rats. Pharmacol Biochem Behav. 1992 Nov;43(3):729–732. doi: 10.1016/0091-3057(92)90401-z. [DOI] [PubMed] [Google Scholar]
  45. Wayner M. J., Armstrong D. L., Polan-Curtain J. L., Denny J. B. Ethanol and diazepam inhibition of hippocampal LTP is mediated by angiotensin II and AT1 receptors. Peptides. 1993 May-Jun;14(3):441–444. doi: 10.1016/0196-9781(93)90129-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES